BOA1

Featured post

#Avian #Influenza #H7N9 in #China: Preventing the Next #SARS (@WHO, Apr. 2 ‘17)

  Title : #Avian #Influenza #H7N9 in #China: Preventing the Next #SARS. Subject : Avian Influenza, H7N9 subtype (Asian Lineage), poultry e...

16 Dec 2016

Weekly #US #Influenza #Surveillance #Report - 2016-17 Influenza, Wk 49 ending December 10, 2016 (@CDCgov, summary)

 

Title:Weekly #US #Influenza #Surveillance #Report - 2016-17 Influenza, Wk 49 ending December 10, 2016

Subject: Seasonal Influenza, weekly US activity surveillance report.

Source: US Centers for Disease Control and Prevention (CDC), FluView, full page: (LINK). Summary, edited.

Code: [     ]

_____

Weekly U.S. Influenza Surveillance Report  - 2016-2017 Influenza Season Week 49 ending December 10, 2016

___

|-- Full report also available as PDF –|

__

All data are preliminary and may change as more reports are received.

 

Synopsis:

  • During week 49 (December 4-10, 2016), influenza activity increased slightly in the United States.
    • Viral Surveillance:
      • The most frequently identified influenza virus subtype reported by public health laboratories during week 49 was influenza A (H3).
      • The percentage of respiratory specimens testing positive for influenza in clinical laboratories increased slightly.
    • Pneumonia and Influenza Mortality:
      • The proportion of deaths attributed to pneumonia and influenza (P&I) was below the system-specific epidemic threshold in the National Center for Health Statistics (NCHS) Mortality Surveillance System.
    • Influenza-associated Pediatric Deaths:
      • No influenza-associated pediatric deaths were reported.
    • Influenza-associated Hospitalizations:
      • A cumulative rate for the season of 1.7 laboratory-confirmed influenza-associated hospitalizations per 100,000 population was reported.
    • Outpatient Illness Surveillance:
      • The proportion of outpatient visits for influenza-like illness (ILI) was 1.9%, which is below the national baseline of 2.2%.
      • Two regions reported ILI at or above their region-specific baseline levels.
      • Puerto Rico experienced high ILI activity, one state experienced moderate ILI activity, New York City and four states experienced low ILI activity, 45 states experienced minimal ILI activity, and the District of Columbia had insufficient data.
    • Geographic Spread of Influenza:
      • The geographic spread of influenza in Puerto Rico was reported as widespread; Guam, the U.S. Virgin Islands, and seven states were reported as regional; the District of Columbia and 22 states reported local activity; 20 states reported sporadic activity; and one state reported no activity.

 

National and Regional Summary of Select Surveillance Components

[HHS Surveillance Regions* - Data for current week: Out-patient ILI† - Number of jurisdictions reporting regional or widespread activity§ - % respiratory specimens positive for flu in clinical laboratories- Data cumulative since October 2, 2016 (week 40): A(H1N1)pdm09 - A (H3) - A (Subtyping not Performed) - B Victoria lineage - B Yamagata lineage - B lineage not performed - Pediatric Deaths]

Influenza test results from public health laboratories only

  • Nation – Normal - 10 of 54 - 4.8% – 85 - 1,201 – 110 – 47 – 29 – 61 – 0
    • Region 1 – Normal - 2 of 6 - 2.0% – 0 – 57 – 0 – 0 – 1 – 0 – 0
    • Region 2 – Elevated - 3 of 4 - 2.9% – 0 – 79 – 2 – 16 – 4 – 3 – 0
    • Region 3 – Normal - 0 of 6 - 1.4% – 10 – 113 – 20 – 2 – 5 – 8 – 0
    • Region 4 – Elevated - 1 of 8 - 7.0% – 7 – 120 – 11 – 4 – 4 – 36 – 0
    • Region 5 – Normal - 1 of 6 - 1.7% – 3 – 79 – 60 – 14 – 4 – 5 – 0
    • Region 6 – Normal - 1 of 5 - 2.3% – 12 – 33 – 0 – 5 – 5 – 1 – 0
    • Region 7 -  Normal - 0 of 4 - 2.0% – 0 – 32 – 1 – 2 – 0 – 0 – 0
    • Region 8 – Normal - 0 of 6 - 3.8% – 29 – 150 – 3 – 0 – 0 – 0 – 0
    • Region 9 – Normal - 1 of 5 - 4.6% – 22 – 321 – 10 – 2 – 6 – 4 – 0
    • Region 10 – Normal - 1 of 4 - 8.6% – 2 – 217 – 3 – 2 – 0 – 4 – 0

___

{*} HHS regions (Region 1 CT, ME, MA, NH, RI, VT; Region 2: NJ, NY, Puerto Rico, US Virgin Islands; Region 3: DE, DC, MD, PA, VA, WV; Region 4: AL, FL, GA, KY, MS, NC, SC, TN; Region 5: IL, IN, MI, MN, OH, WI; Region 6: AR, LA, NM, OK, TX; Region 7: IA, KS, MO, NE; Region 8: CO, MT, ND, SD, UT, WY; Region 9: AZ, CA, Guam, HI, NV; and Region 10: AK, ID, OR, WA).

{†} Elevated means the % of visits for ILI is at or above the national or region-specific baseline

{§} Includes all 50 states, the District of Columbia, Guam, Puerto Rico, and U.S. Virgin Islands

{‡} National data are for current week; regional data are for the most recent three weeks

 

U.S. Virologic Surveillance

WHO and NREVSS collaborating laboratories, which include both public health and clinical laboratories located in all 50 states, Puerto Rico, and the District of Columbia, report to CDC the total number of respiratory specimens tested for influenza and the number positive for influenza by virus type. In addition, public health laboratories also report the influenza A subtype (H1 or H3) and influenza B lineage information for the viruses they test and the age or age group of the persons from whom the specimens were collected.

Additional data are available at http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html and http://gis.cdc.gov/grasp/fluview/flu_by_age_virus.html.

____

The results of tests performed by clinical laboratories during the current week are summarized below.

[Week 49 - Data Cumulative since October 2, 2016 (Week 40)]

  • No. of specimens tested - 15,117 - 157,423
    • No. of positive specimens (%) - 728 (4.8%) - 3,928 (2.5%)
      • Positive specimens by type:
        • Influenza A - 575 (79.0%) - 2,720 (69.2%)
        • Influenza B - 153 (21.0%) - 1,208 (30.8%)

(…)

View National and Regional Level Graphs and Data

____

The results of tests performed by public health laboratories, as well as the age group distribution of influenza positive tests, during the current week are summarized below.

[Week 49 - Data Cumulative since October 2, 2016 (Week 40)]

  • No. of specimens tested – 928 - 10,585
    • No. of positive specimens* – 206 - 1,533
      • Positive specimens by type/subtype:
        • Influenza A - 198 (96.1%) - 1,396 (91.1%)
          • A(H1N1)pmd09 - 6 (3.0%) - 85 (6.1%)
          • H3 - 158 (79.8%) - 1,201 (86.0%)
          • Subtyping not performed - 34 (17.2%) - 110 (7.9%)
        • Influenza B - 8 (3.9%) - 137 (8.9%)
          • Yamagata lineage - 2 (25.0%) - 29 (21.2%)
          • Victoria lineage - 3 (37.5%) - 47 (34.3%)
          • Lineage not performed - 3 (37.5%) - 61 (44.5%)

___

*The percent of specimens testing positive for influenza is not reported because public health laboratories often receive samples that have already tested positive for influenza at a clinical laboratory and therefore percent positive would not be a valid indicator of influenza activity. Additional information is available at http://www.cdc.gov/flu/weekly/overview.htm.

(…)

View National and Regional Level Graphs and Data

(…)

 

Antigenic Characterization

CDC has antigenically characterized 64 influenza viruses [24 influenza A (H1N1)pdm09, 26 influenza A (H3N2), and 14 influenza B viruses] collected by U.S. laboratories since October 1, 2016.

  • Influenza A Virus [50]
    • A (H1N1)pdm09 [24]:
      • All 24 (100%) influenza A (H1N1)pdm09 viruses were antigenically characterized using ferret post-infection antisera as A/California/7/2009-like, the influenza A (H1N1) component of the 2016-2017 Northern Hemisphere vaccine.
    • A (H3N2) [26]:
      • All 26 (100%) influenza A (H3N2) viruses were antigenically characterized as A/Hong Kong/4801/2014-like, a virus that belongs in genetic group 3C.2a and is the influenza A (H3N2) component of the 2016-2017 Northern Hemisphere vaccine, by HI testing or neutralization testing.
  • Influenza B Virus [14]
    • Victoria Lineage [6]:
      • 5 of 6 (83%) B/Victoria-lineage viruses were antigenically characterized using ferret post-infection antisera as B/Brisbane/60/2008-like, which is included as an influenza B component of the 2016-2017 Northern Hemisphere trivalent and quadrivalent influenza vaccines.
    • Yamagata Lineage [8]:
      • All 8 (100%) B/Yamagata-lineage viruses were antigenically characterized using ferret post-infection antisera as B/Phuket/3073/2013-like, which is included as an influenza B component of the 2016-2017 Northern Hemisphere quadrivalent influenza vaccines.

(…)

-

Keywords: Seasonal Influenza; USA; US CDC; Updates.

------